EUVIMEDEUVIMED entdecken
Open Access

Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis

Mafo Kamanda-Kosseh, Stephanie Shiau iD, Sanchita Agarwal iD, Ananya Kondapalli, Ivelisse Colon, Nayoung Kil, Mariana Bucovsky, Joan M Lappe, Julie Stubby, Elizabeth Shane, Adi Cohen iD

The Journal of Clinical Endocrinology & Metabolism · 18.02.2025 · 110 (3) · e791-e801

DOI: 10.1210/clinem/dgae240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.04.2024. Verfasst von Mafo Kamanda-Kosseh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Bone Density, Denosumab, Teriparatide, Bone Density Conservation Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Simon-Strauss Foundation, NIAMS NIH HHS, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

We previously reported that sequential teriparatide followed by denosumab substantially increases bone mineral density (BMD) in premenopausal idiopathic osteoporosis (PremenIOP).

Objective

To determine whether administration of bisphosphonates after denosumab cessation is associated with stable BMD in PremenIOP Design Open-label extension study.

Participants

Twenty-four PremenIOP Teriparatide-Denosumab Study participants.

Interventions

Oral alendronate (ALN), 70 mg weekly, or intravenous zoledronic acid (ZOL), 5 mg once (patient choice), was administered 7 months (M) after final denosumab dose. Outcomes BMD by dual-energy x-ray absorptiometry and serum C-telopeptide (CTX) q6M; Vertebral Fracture Assessment (VFA), and high-resolution peripheral quantitative computed tomography (HR-pQCT) q12 M.

Results

Twenty-four women with PremenIOP (aged 43 ± 8 years), severely affected with low trauma adult fractures (range 0-12; 9 with vertebral fractures) and/or very low BMD, had large BMD increases on sequential teriparatide-denosumab (spine: 25 ± 9%; total hip: 11 ± 6%). During the Bisphosphonate Extension, mean BMD and CTX changes in the entire group were small and not statistically significant at 6 or 12 M. Women choosing ZOL (n = 6) vs ALN (n = 18) did not differ by baseline age, body mass index, fractures, BMD, or CTX. On ZOL, there were small lumbar spine BMD declines and CTX increases, particularly between 6 M and 12 M, while greater stability was observed on ALN. Changes in BMD and CTX did not differ by duration of denosumab (36 M vs <36 M) or between 20 women who remained premenopausal and 4 who transitioned into menopause. Higher pre-teriparatide CTX, likely reflecting baseline remodeling status, predicted more spine and hip bone loss. No new vertebral (clinical or vertebral fraction assessment screening) or nonvertebral fractures occurred.

Conclusion

BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone DensityDenosumabTeriparatideBone Density Conservation AgentsDiphosphonatesOsteoporosisHumansFemaleAdultMiddle AgedPremenopauseZoledronic AcidAbsorptiometry, PhotonDrug Therapy, CombinationAlendronate

Stichwörter der Autor:innen

HR-pQCTalendronatebisphosphonatebone densitybone turnover markersdenosumabpremenopausal osteoporosisteriparatidezoledronic acid

Substanzen

DenosumabTeriparatideBone Density Conservation AgentsDiphosphonatesZoledronic AcidAlendronate

Autor:innen und Institutionen

  • Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ 08854, USA.
  • Osteoporosis Research Center, Creighton University Medical Center, Omaha, NE 68131, USA.

ORCID-Profile: Stephanie Shiau, Sanchita Agarwal, Adi Cohen

Förderung

  • Simon-Strauss Foundation
  • NIAMS NIH HHS
  • Amgen
  • FDA HHS
  • NIH HHS
  • United States Food and Drug Administration Orphan Products Clinical Trials Grants Program
  • National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Kamanda-Kosseh, M., Shiau, S., Agarwal, S., Kondapalli, A., Colon, I., Kil, N., Bucovsky, M., Lappe, J. M., Stubby, J., Shane, E., & Cohen, A. (2025). Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 110(3), e791-e801. https://doi.org/10.1210/clinem/dgae240

Vancouver

Kamanda-Kosseh M, Shiau S, Agarwal S, Kondapalli A, Colon I, Kil N, et al. Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2025;110(3):e791-e801. doi:10.1210/clinem/dgae240

BibTeX
@article{KamandaKosseh2025,
  author = {Kamanda-Kosseh, Mafo and Shiau, Stephanie and Agarwal, Sanchita and Kondapalli, Ananya and Colon, Ivelisse and Kil, Nayoung and Bucovsky, Mariana and Lappe, Joan M and Stubby, Julie and Shane, Elizabeth and Cohen, Adi},
  title = {Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {3},
  pages = {e791--e801},
  doi = {10.1210/clinem/dgae240}
}
Kostenlos starten →